The growth of the EPS is critical in understanding the current valuation of Arrowhead Pharmaceuticals. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -41.20 % over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is Christopher Anzalone. Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
Previous Intraday Performance:
The ARWR shares had a previous change of -0.62% which opened at 14.50 and closed at 14.52. It moved to an intraday high of 14.83 and a low of 14.30.
Business Wire: Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
Historical Performance:
Over the last five trading days, ARWR shares returned 7.56% and in the past 30 trading days it returned 11.26%. Over three months, it changed -1.49%. In one year it has changed 278.13% and within that year its 52-week high was 22.39 and its 52-week low was 3.01. ARWR stock is 382.39% above its 52 Week Low.
Our calculations result in a 200 day moving average of 12.12 and a 50 day moving average of 14.58. Right now, ARWR stock is trading 19.82% above its 200 day moving average.
Business Wire: Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results
Liquidity:
The company has a market cap of $1.3b with 88.0m shares outstanding and a float of 83.1m shares. Trading volume was 1,083,283 shares and has experienced an average volume of 1,691,689 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Arrowhead Pharmaceuticals was -0.47 which ended on 30th of September 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.19.
Below was the last reported quarterly earnings per share:
06-30-2018: -0.18
03-31-2018: -0.18
12-31-2017: -0.18
09-30-2017: -0.14
Indicators Also to Watch:
Based on the latest filings, there is 33.50% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.96
PR Newswire: Bancorp 34, Inc. Announces Adoption Of Repurchase Program
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -55.97%, return on assets is -47.20%, price-to-sales is 263.13 and price-to-book is 12.49.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: Arrowhead Pharmaceuticals, ARWR, Biotechnology, Healthcare
